CD274 and neoplasm: Additionally, using anti-PD-1 antibodies conjugated with the enzyme adenosine deaminase, which converts adenosine to inosine, or bispecific fusion proteins targeting PD-(L)1 and TGF-β could help reduce Tregs and revitalize tumor-specific effector T cells [171, 172].